FIBROGEN INC — Director's Dealing 2023

Feb 24, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: FIBROGEN INC (FGEN)
CIK: 0000921299
Period of Report: 2023-02-21

Reporting Person: Eisner Mark (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-21	Common Stock	A	32500	$0.00	Acquired	173683	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-21	Stock Option (Right to Buy)	$22.60	A	55000	Acquired	2033-02-20	Common Stock (55000)	Direct

Footnotes

F1: Represents the grant of restricted stock units (RSUs). Twenty-five percent of the RSUs will vest on March 6, 2024, and the remainder of the RSUs will vest in equal amounts quarterly thereafter for the following three years.

F2: Twenty-five percent of the shares subject to the option will vest on March 1, 2024, and the remainder of the options will vest in equal amounts quarterly thereafter for the following three years.